Who are administration of Cimzia®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cimzia, Abrilada, Humira, Remicade, Infliximab [infliximab biosimilar 3], Etanercept + Acitretin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/administration-of-cimzia.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

administration of Cimzia® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

administration of Cimzia® (administration of Cimzia®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

phase 3 TNF inhibitor TNF Immunology Small molecule Live · refreshed every 30 min

Target snapshot

administration of Cimzia® (administration of Cimzia®) — University Hospital, Ghent. Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
administration of Cimzia® TARGET	administration of Cimzia®	University Hospital, Ghent	phase 3	TNF inhibitor	TNF
Cimzia	CERTOLIZUMAB PEGOL	UCB	marketed	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Remicade	Infliximab-Dyyb	Johnson & Johnson	marketed	TNF blocker	Tumor Necrosis Factor alpha (TNFα)	1998-01-01
Infliximab [infliximab biosimilar 3]	infliximab-infliximab-biosimilar-3	Pfizer	marketed	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)
Etanercept + Acitretin	Etanercept + Acitretin	Pfizer	marketed	TNF inhibitor + retinoid combination	TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

University Hospital, Montpellier · 2 drugs in this class
Amgen · 1 drug in this class
Biogen · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Abbott · 1 drug in this class
Spanish Clinical Pharmacology Society · 1 drug in this class
Takeda · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). administration of Cimzia® — Competitive Intelligence Brief. https://druglandscape.com/ci/administration-of-cimzia. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab